Cancer survival rates have reached an all-time high, with 70 percent of patients now surviving at least five years after diagnosis, according to a recent report by the American Cancer Society (ACS). This significant increase in survival rates is attributed to advancements in detection and treatment, as well as a decrease in smoking rates.
The report highlights the progress made in the fight against cancer, with some of the most fatal cancers seeing the greatest improvements in survival rates. For example, the five-year relative survival rate for myeloma has nearly doubled since the 1990s, jumping from 32 to 62 percent. Similarly, liver cancer survival rates have more than tripled, from 7 to 22 percent.
These improvements are largely due to a better understanding of the cancer genome and the development of targeted therapies that specifically target cancer mutations. As a result, people are now living longer with metastatic cancer, turning what was once considered a death sentence into a chronic disease.
However, the report also warns of challenges ahead. With an estimated two million new cancer cases and over 625,000 deaths expected in 2026, lung cancer remains a leading cause of cancer-related deaths. The authors of the report caution that cuts to federal funding for cancer research could hinder the progress made in recent years.
Despite the advancements in cancer treatment and research, the authors stress the importance of continued investment in cancer-related research to ensure that progress is not halted. Federal funding cuts could limit access to life-saving drugs and impede further advancements in cancer care.
As we celebrate the progress made in cancer survival rates, it is crucial to remember the ongoing challenges in the fight against cancer. Continued support for cancer research and access to innovative treatments are essential to improving outcomes for cancer patients and reducing the burden of this disease on individuals and society.
